ZA986084B - CTL epitopes from EBV - Google Patents

CTL epitopes from EBV

Info

Publication number
ZA986084B
ZA986084B ZA986084A ZA986084A ZA986084B ZA 986084 B ZA986084 B ZA 986084B ZA 986084 A ZA986084 A ZA 986084A ZA 986084 A ZA986084 A ZA 986084A ZA 986084 B ZA986084 B ZA 986084B
Authority
ZA
South Africa
Prior art keywords
seq
ebv
cytotoxic
cell epitopes
present
Prior art date
Application number
ZA986084A
Other languages
English (en)
Inventor
Martina Alison Sherritt
Scott Renton Burrows
Rajiv Khanna
Original Assignee
Queensland Inst Med Res
Commw Scient Ind Res Org
Walter & Eliza Hall Inst Med
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queensland Inst Med Res, Commw Scient Ind Res Org, Walter & Eliza Hall Inst Med, Csl Ltd filed Critical Queensland Inst Med Res
Publication of ZA986084B publication Critical patent/ZA986084B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA986084A 1997-07-10 1998-07-09 CTL epitopes from EBV ZA986084B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPO7841A AUPO784197A0 (en) 1997-07-10 1997-07-10 Treatment of nasopharyngeal carcinoma

Publications (1)

Publication Number Publication Date
ZA986084B true ZA986084B (en) 1999-01-26

Family

ID=3802132

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA986084A ZA986084B (en) 1997-07-10 1998-07-09 CTL epitopes from EBV

Country Status (11)

Country Link
US (2) US6723695B1 (de)
EP (1) EP1003773B1 (de)
JP (1) JP2001509514A (de)
CN (1) CN100526331C (de)
AT (1) ATE418562T1 (de)
AU (1) AUPO784197A0 (de)
CA (1) CA2294732A1 (de)
DE (1) DE69840383D1 (de)
NZ (1) NZ501944A (de)
WO (1) WO1999002550A1 (de)
ZA (1) ZA986084B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115786509A (zh) * 2022-10-21 2023-03-14 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种鼻咽癌患病风险预测试剂盒

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642008B1 (en) 1999-11-24 2003-11-04 Oklahoma Medical Research Foundation Assays and therapies for latent viral infection
GB0210682D0 (en) * 2002-05-09 2002-06-19 Glaxosmithkline Biolog Sa Novel use
US20070048329A1 (en) * 2002-11-07 2007-03-01 Rajiv Khanna Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
ATE516045T1 (de) 2003-01-24 2011-07-15 Univ Massachusetts Medical Identifikation von vaccinia-virus-dominanten t- zell-epitopen
US8067535B2 (en) 2003-01-24 2011-11-29 The University Of Massachusetts Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes
FR2850384A1 (fr) * 2003-01-28 2004-07-30 Centre Nat Rech Scient Antigenes mimant les domaines extracellulaires de proteines membranaires de type iii issues de microorganismes intracellulaires pathogenes, anticorps conformationnels derives, et leurs applications
US8451808B2 (en) 2006-02-18 2013-05-28 Intel Corporation Techniques for 40 megahertz (MHz) channel switching
EP1826264A1 (de) * 2006-02-24 2007-08-29 Deutsches Primatenzentrum GmbH Primatmodell für Orthopoxvirus-Infektionen
GB0706070D0 (en) * 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
SG10201407519TA (en) * 2009-11-19 2015-01-29 Univ Singapore Method For Producing T Cell Receptor-Like Monoclonal Antibodies And Uses Thereof
AU2011295845B2 (en) * 2010-09-01 2016-09-22 Baylor College Of Medicine EBV-specific cytotoxic T-lymphocytes for the treatment of locoregional nasopharyngeal carcinoma (NPC)
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
EP2791322A1 (de) 2011-12-12 2014-10-22 Cell Medica Limited Verfahren zur expansion von t-zellen
US20150010519A1 (en) 2012-02-09 2015-01-08 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
WO2013139789A1 (en) 2012-03-19 2013-09-26 Deutsches Krebsforschungszentrum B-cell receptor complex binding proteins containing t-cell epitopes
AU2013332272B2 (en) 2012-10-19 2018-12-20 The Council Of The Queensland Institute Of Medical Research Improved human herpesvirus immunotherapy
CA2953747A1 (en) 2013-06-28 2014-12-31 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
US10016494B2 (en) 2014-02-07 2018-07-10 Valorisation-Hsj, Limited Partnership Antigenic epitopes from EBV gp350/220 and uses thereof
KR20230039751A (ko) 2014-04-15 2023-03-21 그리피스 유니버시티 그룹 a 스트렙토코쿠스 백신
CN113768952A (zh) 2014-11-05 2021-12-10 纪念斯隆-凯特林癌症中心 选择用于过继细胞疗法的t细胞系及其供体的方法
WO2016103192A1 (en) 2014-12-23 2016-06-30 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
NZ736675A (en) 2015-05-12 2023-03-31 Memorial Sloan Kettering Cancer Center Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy
KR101794304B1 (ko) * 2015-09-01 2017-11-06 가톨릭대학교 산학협력단 Ｅｂｖ 항원 특이 ｔ―세포 수용체 및 이의 용도
WO2017049291A1 (en) 2015-09-18 2017-03-23 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
SG11201804683RA (en) * 2015-12-04 2018-06-28 Agency Science Tech & Res Clinical correlates of immunotherapy efficacy
EA201891639A1 (ru) 2016-02-26 2019-06-28 Окленд Юнисервисес Лимитед Аминокислотные и пептидные конъюгаты и способ конъюгации
CN109475578A (zh) * 2016-05-25 2019-03-15 昆士兰医学研究所理事会 使用同种异体t细胞治疗自身免疫疾病的方法
FI3507300T3 (fi) 2016-09-02 2023-04-03 Univ James Cook Haavaa parantava peptidi
WO2018057823A1 (en) 2016-09-23 2018-03-29 Memorial Sloan Kettering Cancer Center Generation and use in adoptive immunotherapy of stem cell-like memory t cells
CN106397574A (zh) * 2016-10-21 2017-02-15 上海交通大学医学院附属新华医院 抗原表位肽及其应用
AU2017358401B2 (en) 2016-11-09 2022-01-13 Griffith University Subtilase cytotoxin B subunit mutant
CN107267481A (zh) * 2017-05-09 2017-10-20 上海交通大学医学院附属新华医院 Cdk5抗原表位肽及其应用
AU2018355145A1 (en) 2017-10-23 2020-04-30 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
NL2023863B1 (en) 2019-09-20 2021-05-25 Univ Griffith Protein particles and uses thereof
US20230181709A1 (en) 2019-11-25 2023-06-15 Griffith University Immunogenic protein against gonococcal infection
CN113621070A (zh) 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用
MX2023004016A (es) * 2020-10-07 2023-05-04 Council Queensland Inst Medical Res Vacunas de poliepitopo del herpesvirus.
EP4232076A1 (de) 2020-10-20 2023-08-30 The Chancellor, Masters and Scholars of The University of Oxford Verfahren und zusammensetzungen zur behandlung von epstein-barr-virus-assoziiertem krebs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3583564D1 (de) 1984-08-23 1991-08-29 Hans Joachim Wolf Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
WO1993019092A1 (fr) 1992-03-19 1993-09-30 Centre National De La Recherche Scientifique Adenovirus recombinants defectifs exprimant des proteines caracteristiques du virus epstein-barr
AU1942595A (en) * 1994-03-16 1995-10-03 Csl Limited Cytotoxic t-cell epitopes
AUPM446594A0 (en) 1994-03-16 1994-04-14 Csl Limited Cytotoxic t-cell epitopes identified within epstein-barr virus
MY114769A (en) * 1994-04-18 2003-01-31 Aviron Inc Non-splicing variants of gp350/220
CA2195642A1 (en) 1994-07-27 1996-02-08 Andreas Suhrbier Polyepitope vaccines
AU3072395A (en) * 1994-07-27 1996-02-22 Csl Limited Polyepitope vaccines
GB9501300D0 (en) 1995-01-24 1995-03-15 Boughton Brian J Peptides which inhibit viruses
AU712364B2 (en) * 1996-05-24 1999-11-04 Council Of The Queensland Institute Of Medical Research, The EBV CTL epitopes
AUPO007396A0 (en) 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115786509A (zh) * 2022-10-21 2023-03-14 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种鼻咽癌患病风险预测试剂盒

Also Published As

Publication number Publication date
NZ501944A (en) 2001-11-30
CA2294732A1 (en) 1999-01-21
JP2001509514A (ja) 2001-07-24
US20030152582A1 (en) 2003-08-14
ATE418562T1 (de) 2009-01-15
CN1269804A (zh) 2000-10-11
EP1003773B1 (de) 2008-12-24
AUPO784197A0 (en) 1997-08-07
EP1003773A1 (de) 2000-05-31
DE69840383D1 (de) 2009-02-05
EP1003773A4 (de) 2002-08-07
WO1999002550A8 (en) 2000-06-15
CN100526331C (zh) 2009-08-12
WO1999002550A1 (en) 1999-01-21
US6723695B1 (en) 2004-04-20

Similar Documents

Publication Publication Date Title
ZA986084B (en) CTL epitopes from EBV
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
NZ335612A (en) A composition containing cytotoxic specificT-cell epitopes being either Rev and/or Tat proteins from HIV virus for prevention and treatment of human immunodeficiency virus (HIV) infection
WO1999051748A3 (en) Fusion proteins of mycobacterium tuberculosis antigens and their uses
FR12C0004I1 (de)
AU3173297A (en) Exendin analogues, processes for their preparation and medicaments containing them
CY2570B1 (en) Compounds for immunotherapy and diagnosis of tuberculosis
CA2011878A1 (en) Immunogenic regions on the e7 protein of human papillomavirus type 16
CA2168583A1 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
GB2301591A (en) Cytotoxic T-cell epitopes
EP1375511A3 (de) Peptide zum Induzieren einer Antwort der zytotoxischen T-Lymphozyten gerichtet gegen das Hepatitis-B-Virus
EP0830456A4 (de) ISOLIERTES FrpB NUKLEINSÄUREMOLEKÜL UND ENTSPRECHENDE IMPFSTOFF
GB2332907B (en) EBV CTL Epitopes
EP0770624A3 (de) Peptid das eine Immunantwort gegen menschlichen Magenkrebs induziert und Arzneimittel die es enthält zur Vorbeugung oder Behandlung von Magenkrebs
GB8917256D0 (en) Biological preparation and its use
CA2109977A1 (en) Giardia vaccines
WO1998039027A3 (en) Sialyl lewis antigens as targets for immunotherapy
EP1028754A4 (de) Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen
WO2000055194A3 (en) Tuberculosis antigens and methods of use therefor
ZA971403B (en) Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof.
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
SE9600436D0 (sv) Vaccine against hantavirus
NZ316110A (en) vaccine containing an antigen from H. Influenzae and an antigen from influenza virus
CA2156416A1 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
WO2000024876A3 (en) Spumavirus isolated from humans